Ontology highlight
ABSTRACT:
SUBMITTER: Camporota L
PROVIDER: S-EPMC2230611 | biostudies-literature | 2007
REPOSITORIES: biostudies-literature
Critical care (London, England) 20070101
In November 2001, drotrecogin alfa (activated) was approved by the US Food and Drug Administration; in August 2002 it was approved by the European Medicines Agency. Since the approval of drotrecogin alfa (activated), however, critical care physicians have been faced with several challenges, namely its costs, selection of patients who are more likely to benefit from it, and the decision regarding when to start drotrecogin alfa (activated) treatment. There are also operational issues such as how t ...[more]